VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2020 | Hypomethylating agent based combinations in MDS

Thomas Prebet, MD, PhD, Yale School of Medicine, New Haven, CT, discusses a key strategy to find novel agents to use in combination with hypomethylating agents (HMAs) in higher-risk myelodysplastic syndromes (MDS). The end goal is to improve patient outcomes while mitigating increased side effects, such as hematological toxicity, that are often intolerable in vulnerable populations. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Thomas Prebet, MD, PhD, has done consultancy work for BMS and AbbVie and has received research support from BMS and Jazz.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter